Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01140503 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01140503: Clinical Trial NA study, sponsored by Stanford University.
NCT01140503 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01140503, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and efficacy of an oral medicine (called apremilast) for treating skin involvement in patients with the disease dermatomyositis.
Interventions
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01140503
The ClinicalTrials.gov registry entry for NCT01140503 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apremilast is the first listed.
NCT01140503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01140503 about?
NCT01140503 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis". This study is designed to evaluate the safety and efficacy of an oral medicine (called apremilast) for treating skin involvement in patients with the disease dermatomyositis.
What is the current status of trial NCT01140503?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2010-02. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01140503?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT01140503?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.